Liposomal nanoformulations of cannabidiol with celecoxib or 2,5-dimethylcelecoxib as a novel treatment option for glioblastoma multiforme
2021/43/O/NZ5/02346
Keywords
Descriptors
- NZ5_003: Patogeneza chorób człowieka
- NZ5_007: Leczenie chorób człowieka
Panel
NZ5 – Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
Voivodeship: wielkopolskie
Principal investigator (from the host institution)
dr hab. Violetta Katarzyna Krajka-Kuźniak
Number of co-investigators in the project: 2
Call
PRELUDIUM BIS 3 – announced on 2021-09-15
- Amount awarded
- 602 490 PLN
- Project start date
- 2022-10-01
- Project end date
- 2026-09-30
- Project duration
- 48 months (the same as in the proposal)
- Project status
- Pending project
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (2)
-
The application of cannabidiol in the treatment of glioblastoma
- Authors:
- Rybarczyk, A.; Majchrzak-Celińska, A.; Krajka-Kuźniak, V
- Academic press:
- Acta Poloniae Pharmaceutica -Drug Research (year: 2023, volume: 80, pages: 207-217), Publisher: Polskie Towarzystwo Farmaceutyczne
- Status:
- Published
- DOI:
- 10.32383/appdr/163414 – link to the publication
-
Targeting Nrf2 Signaling Pathway in Cancer Prevention and Treatment: The Role of Cannabis Compounds
- Authors:
- Rybarczyk, A.; Majchrzak-Celińska, A.; Krajka-Kuźniak, V.
- Academic press:
- Antioxidants (year: 2023, volume: 12, pages: 46042), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/antiox12122052 – link to the publication